EC HEALTHCARE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.51 HKD | -0.66% |
|
-9.04% | -13.22% |
| May. 13 | Hong Kong Bourse Allows EC Healthcare to Delay Circular Dispatch for Proposed Acquisition | MT |
| May. 06 | EC Healthcare Sales Volume Unchanged for Q2 of Fiscal 2024 | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 48% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- With a 2024 P/E ratio at 36.41 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Personal Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -13.22% | 230M | - | ||
| -16.70% | 550M | D+ | ||
| +35.74% | 456M | - | ||
| -26.97% | 376M | - | ||
| -8.19% | 247M | - | ||
| -25.93% | 93.29M | - | ||
| -3.77% | 80.3M | - | ||
| -1.64% | 79.99M | - | ||
| -20.69% | 58.82M | - | - | |
| -13.46% | 53.49M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 2138 Stock
- Ratings EC Healthcare
